Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CBIO vs CGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: CBIO 1 – 5 CGEN Matrix Metrics: CBIO 2 – 8 CGEN

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CBIO carries a Unified Composite Score of 42.4/100 (HOLD) at $13.04 (N/M Forward P/E, -1228.4% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).

  • Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.6); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CBIO vs CGEN
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.04
-3.41% 1D
Market Cap $564.1M
TTM Revenue $15M
Forward P/E N/M
Beta / 30D Vol 1.39β · 59% Vol
Unified Composite Score
42.4 / 100 HOLD
Tech 36.0 Fund 51.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.6 · SMA20: $13.51 · SMA50: $14.51
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18

6-Pillar Scorecard Institutional Category Breakdown (CBIO 1 – 5 CGEN)

Columns: Metric · CBIO · CGEN
1. Valuation Multiples CGEN
Forward P/E N/M 12.4x
Trailing P/E N/M 5.2x
PEG Ratio N/M 1.29x
EV / Revenue 26.3x 2.5x
2. Growth & Scale CGEN
Revenue Growth (YoY) +0.0% +102.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $15M $76M
Market Cap $564.1M $193.2M
3. Profitability & Quality CGEN
Gross Margin 100.0% 86.2%
Operating Margin -1228.4% 41.3%
Net Profit Margin 0.0% 47.9%
Return on Equity (ROE) -160.8% 57.2%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) -$154M $32M EBITDA
Cash Flow Margin N/A 41.9% EBITDA Mgn
Net Cash / Leverage $170M Net Cash $4.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CBIO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 127.8% (29th %ile) 89.7% (57th %ile)
Put/Call OI Skew 1.07x (Balanced) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CGEN
OpEx & R&D Intensity N/A 44.9% of Rev ($34M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CBIO (2) vs CGEN (8)
Institutional Metric CBIO CGEN Criterion Row Edge
Market Capitalization
Scale
$564.1M $193.2M Larger Scale CBIO
Trailing P/E Ratio
Valuation
N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio
Valuation
N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
+0.0% +102.1% Higher Growth CGEN
Operating Margin (TTM)
Profitability
-1228.4% 41.3% Higher Margin CGEN
Net Profit Margin
Profitability
0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
-160.8% 57.2% Higher ROE CGEN
52-Week Range Position
Momentum
23% ($9–$27) 33% ($1–$3) Stronger Trend CGEN
Beta / 30D Volatility
Risk Regime
1.39β · 59% Vol 1.44β · 62% Vol Lower Realized Risk CBIO
Unified Institutional Score
Composite Signal
42.4 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite CGEN
Trailing 12M Revenue (USD)
Operating Scale
$15M $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 86.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 26.3x EV/Rev 1.29x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$154M ($170M Net Cash) $32M EBITDA ($4.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CBIO +2.96 pp
CBIO: +5.5% · CGEN: +2.54%
3M Horizon CGEN +7.5 pp
CBIO: -24.71% · CGEN: -17.21%
6M Horizon CGEN +3.43 pp
CBIO: -29.44% · CGEN: -26.01%
1Y Horizon CGEN +23.02 pp
CBIO: +0.15% · CGEN: +23.17%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CBIO Revenue CGEN Revenue CBIO Op. Margin CGEN Op. Margin Margin Leader
FY2016 $0M $0M -172505.3% -4576.3% CGEN
FY2018 N/A $20M N/A -130.5% CGEN
FY2020 $10M $0M -506.8% -1574.8% CBIO
FY2021 $0M $10M -5470.7% -584.6% CGEN
FY2022 $0M $10M -63204.4% -471.7% CGEN
FY2023 $0M $30M -392752.9% -38.8% CGEN
FY2024 N/A $30M N/A -53.4% CGEN
FY2025 $10M $70M -1407.5% 43.1% CGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CBIO BREAKDOWN
145d in phase · OBV NEUTRAL
Current IV 127.8%
IV Percentile 29th %ile
Put/Call OI Skew 1.07x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $564.1M market capitalization and -1228.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published

Investor FAQ CBIO vs CGEN Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CBIO carries a Unified Composite Score of 42.4/100 (HOLD) at $13.04 (N/M Forward P/E, -1228.4% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.6); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEN leads the Growth & Scale pillar: CBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), CBIO cumulative revenue shifted +0.0% while CGEN shifted +250.0%. In operating R&D and SG&A reinvestment, CBIO deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.

CGEN screens cheaper on headline valuation multiples. CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.3x EV/Revenue (unreported FCF margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBIO (-160.8% ROE) versus CGEN (57.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CBIO carries 127.8% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 59% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.